Description: Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Home Page: www.shieldtherapeutics.com
Northern Design Centre
Gateshead,
NE8 3DF
United Kingdom
Phone:
44 1915 118 500
Officers
| Name | Title |
|---|---|
| Mr. Anders Lundstrom | Interim CEO & Independent Non-Executive Director |
| Dr. Christian Schweiger M.D., Ph.D. | Co-Founder & Non Executive Director |
| Mr. Santosh Shanbhag | Chief Financial Officer |
| Ms. Lucy Kate Huntington-Bailey | General Counsel & Company Secretary |
| Ms. Suzanne Wood | Group HR Director |
| Ms. Carol Akinola | Head of Pharmacovigilance & Medical Information |
| Mr. Andrew Hurley | Chief Commercial Officer |
| Kate Armanetti | Senior Director of People & Culture |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 64.5161 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 51.2612 |
| Price-to-Sales TTM: | 1.254 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 73 |